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Methods: A review of academic clinical trials and documents dealing 
with the proper conduct of clinical trials was combined with both 
personal and published regulatory experience concerning the quality 
of data produced by academic clinical trials.
Results: Academic clinical trials often produce data that are not 
accepted by regulatory authorities for the approval or labeling of 
the treatments studied in the trials. Participants in such trials are 
therefore exposed to risks without producing any personal or societal 
benefits; by definition, such trials are unethical.
Conclusions: It is proposed that only clinical studies, including those 
done by academics, that are designed, conducted and monitored in 
such a way as to produce data suitable for regulatory approval should 
be funded, approved by institutional review boards/ethics commit-
tees, or conducted in the developed or developing world. Increased 
training of academic investigators, institutional review boards/ethics 
committees, as well as the public and private groups that fund clini-
cal trials, are needed to decrease the number of unethical academic 
clinical trials performed.
Key words: academic clinical trials, developing world, ethics, regula-
tory approval.
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Background: Proposal writing is a skill of fundamental importance 
to the researchers, and the proposal is an important step in develop-
ing a research project that gives an overview of it. It enables other 
people to understand the scope of the research and the significance 
of the research, as well as the proposed methodology and chosen 
research method. The purpose of this paper is to define the research 
proposal and review its importance and its different types. It also 
provides a generic outline that focuses on the components and sec-
tions of the research proposal and the basic format of each section.
Objectives: The main objectives are to highlight the importance of 
writing a research proposal. It also aims to define the research and 
its different types as well as to identify the components and sections 
of a research proposal and to explain the content of each section.
Methods: A comprehensive literature review on research proposal writ-
ing has been conducted by using academic databases and some search 
engines. The focus was on the general format, guidelines, and presenta-
tion that suit students and scholars in different disciplines of life sciences. 
Various sections of a research proposal are discussed in detail. The focus 
is to motivate young researchers to take up challenging problems.
Results: The basic definitions of research and proposal in general and 
in health in particular were given and explained. Useful guidelines 
for the identification and selection of a research topic were also dis-
cussed in detail. The questions relating to whether a research problem 
is adequately analyzed and whether it is clearly stated were also 
addressed. Development of research objectives and literature reviews 
were also discussed. A special emphasis was given to elements of the 
“Methods” section of a research proposal, as well as the development 
of a work plan, and the preparation of a budget was highlighted.
Key words: proposal, research, research health system, research 
methodology.
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Background: Ever since the 1996 revision of the Declaration of 
Helsinki, the World Medical Association has attempted to address 
ethical and scientific concerns of its diverse stakeholders for Articles 
33 (use of placebo) and 34 (posttrial provisions), most recently in 
2013. Both are inextricably linked to standard of care, an essential 
element of any comparative, interventional clinical trial. But has 
this now 20-year-long ethical debate truly been put to rest? The 
choice of standard of care in clinical trials remains a complex issue, 
particularly for comparative trials conducted in emerging countries. 
Interpretations of the Declaration of Helsinki as the cornerstone 
document for medical ethics range from best intervention available 
worldwide to any locally available standard of care for the compara-
tor group, which in the worst case could mean no interventional 
care at all.1,2
Objectives: Our aim was to examine the current status of clinical 
research practice and ethical guidance on standard of care, with a 
focus on international health research, and to review corresponding 
guidance issued by pharmaceutical sponsors in their publicly acces-
sible policies on clinical research.
Methods: We reviewed ethical recommendations before and after 
2013 and scientific literature, as well as major clinical trial registries 
(European Union, United States, and World Health Organization), 
to assess current clinical research practice related to standard of 
care. Furthermore, the websites of the top-ranked 25 pharmaceuti-
cal companies on sales figures in 20143 were reviewed for publicly 
accessible policies with reference to standard of care in clinical trials 
in emerging regions.
Results: After a period of active scientific-ethical debate before the 
2013 revision of the Declaration of Helsinki, few ethical discussions 
or recommendations have since been published that could provide 
additional guidance to clinical researchers. The recent scientific lit-
erature reflects the continued challenge for researchers to design 
an ethically and scientifically sound study, especially in vulnerable 
populations. However, ~20% of registered open clinical trials across 
major trial registries are designed with a placebo control, suggest-
ing that the question of standard of care remains highly pertinent. 
The review of pharmaceutical sponsor websites revealed a highly 
variable picture with regard to publicly available policies or state-
ments on this issue, particularly for research conducted in low- to 
middle-income countries. The review outcome spans results from 
any policy published to very clearly worded statements on clinical 
research in developing countries, the standard of care aspect dur-
ing the trial conduct, and regulatory strategies after completion of 
product development.
Conclusions: Investigators, ethics committees, and sponsors continue 
to be confronted with the challenge of ensuring ethically and scien-
tifically sound clinical studies with appropriate standard of care. We 
have attempted to examine available ethical guidance and summarize 
recommendations for clinical trial designs that could assist in address-
ing these challenges. Care should be taken to maintain a high level 
of awareness for the importance of a sound ethical framework for a 
scientifically valid clinical trial design. Pharmaceutical companies, as 
major sponsors of clinical research, should demonstrate awareness and 
an appropriate management of these aspects, particularly in regions 
with limited resources. As part of the ongoing debate on transparency, 
one option could be to formulate positions and make them available to 
the public, regardless of whether such a statement is legally required. 
A few examples already exist where such clarifying statements have 
been provided. This approach would prepare the ground for an open 
and transparent communication to agencies, ethics committee, and, 
last but not least, patients.
Key words: bioethics, clinical research, Declaration of Helsinki, 
international health research, placebo, standard of care.
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Background: Type 2 diabetes mellitus (T2DM) is a chronic lifestyle 
disease. It has become evident that T2DM occurs even among the 
younger age groups.1 In Lebanon, T2DM has a major public health 
impact through high disease prevalence, significant downstream 
pathophysiologic effects, and enormous financial liabilities.2
Objectives: The aim of this study was to determine the risk of T2DM 
among undergraduate students from Ashrafieh city by using the vali-
dated Diabetes Risk Score Questionnaire. This study also offered 
T2DM education and awareness to respondents.
Methods: A cross-sectional study was conducted by using a validated 
questionnaire. Of the total 100 students approached, 79 accepted to par-
ticipate in the study. Respondents were interviewed and scored by using 
the Diabetes Risk Score Questionnaire on the basis of 4 parameters: 
age, abdominal obesity, physical activity, and family history of diabetes.
Results: : Of 79 students screened by using the Diabetes Risk Score 
Questionnaire, 39 (49%) were male, and 40 (51%) were female. In 
description, 23 (29%) respondents were not doing any exercise, and 
only 40 (51%) respondents were without abdominal obesity. Overall, 
10%, 44%, and 46% of the respondents were found to be in the high, 
moderate, and low diabetes risk groups, respectively.
Conclusions: According to the International Diabetes Federation, the 
projected prevalence of T2DM among adults in Lebanon for 2020 is 
20.4%. Our study found that only 46% of respondents were in the low-
risk category. Thus, it is essential to enhance awareness among the youth 
regarding T2DM and also of obesity and physical activity, as most of the 
respondents were found to lead a sedentary lifestyle. Therefore, as per 
the study plan at the end of the questionnaire, a booklet on “Diabetes 
Prevention Advice” was provided to all the respondents.
Key words: Lebanon, type 2 diabetes mellitus.
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A compulsory license state-order is limiting the effects of an indus-
trial property right. To obtain a compulsory license, a licensee must 
first have tried unsuccessfully to obtain the property right of a license 
from the owner. Furthermore, this property right has to be in effect 
and in place. The licensee must have the ability and the willingness 
to use the intellectual property right for his own account. Thus, 
a compulsory license cannot be assigned to third parties. If these 
aforementioned conditions are met, there are 2 conditions for grant-
ing a compulsory license: (1) the licensee has a licensing related to 
the dependent property rights, which is an essential advancement of 
the patented technology; or (2) there is a public interest in granting 
a compulsory license, which is much more common in the case of 
pharmaceutical patents. Normally, public interest is defined that a 
medical treatment method or a drug (in the legal sense) should be 
accessible for each person in principle. This accessibility is not been 
given if a treatment method or a drug is only offered subjectively 
too expensive. Rather, a particularly high benefit must be claimed; 
e.g. initial treatment option of common diseases with good pros-
pects of efficacy, e.g. the domestic market is insufficient supplied or 
if the drug or the investigational medicinal product has much less 
side effects so far. Public interest is, in this case not stated, if the 
treatment results can be achieved with other, more or less equiva-
lent, alternatives. For example, the European Union (EU) published 
on May 17, 2006, a Regulation (EC Regulation No. 816/2006) 
on compulsory licensing of patents relating to the manufacture of 
pharmaceutical products for export to countries with public health 
problems. This regulation establishes a procedure for companies 
in the EU wishing to manufacture generic medicines for use in the 
developing world to apply for a compulsory license from a patent 
holder, which allows their manufacture. The legislation is part of 
wider EU action to tackle public health concerns that the world’s 
least developed and developing countries face, in particular access 
to safe, effective, and affordable medicines. This article compares 
arguments of both opponents and proponents of compulsory licens-
ing, which is a legitimate safeguard provided under the EU and in 
the same line as the TRIPS (Agreement on Trade-Related Aspects 
of Intellectual Property Rights by the World Trade Organization) 
to check misuse of monopoly and to deal with situations of public 
health crisis, especially in the Third World.
Key words: access to drugs, compulsory licensing, pharmaceutical 
patents, public health, TRIPS flexibility.
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Background: The lives of far too many in the world are being 
blighted and cut short by age- and lifestyle-related chronic diseases 
such as heart disease, stroke, cancer, chronic respiratory diseases, and 
diabetes resulting from urbanization, sedentary lifestyles, changing 
diets, and rising obesity levels. 1Even problems of child overweight 
and obesity are increasing worldwide, leading to a growing inci-
dence of type 2 diabetes. India is the second most populated country 
with a population of > 1.2 billion. Along with this, India’s working 
population is also increasing, which will help the Indian economy 
to grow at a much faster rate than the other emerging economies. 
The working population in India is expected to be close to 64% in 
2026. However, with the increase in the young working population 
and change in lifestyle of this young population, there has been an 
increase in lifestyle-related diseases. The current generation, which 
is used to deskbound work, alcohol consumption, and smoking, 
is more prone to such lifestyle-related diseases.2 It is of great con-
cern to observe elevations in the key risk factors that contribute to 
chronic diseases: use of alcohol/tobacco, obesity, and environmental 
